Kainos Laboratories, Inc. (JP:4556)
:4556
Top Page
Kainos Laboratories, Inc.
(4556)
Select Model
Select Model
Rating:85Outperform
Price Target:
¥2,660.00
▲(109.28% Upside)
Action:UpgradedDate:02/10/26
The score is driven primarily by strong financial performance (profitability, low leverage, and especially strong free cash flow growth) and an attractive valuation (low P/E with a solid dividend yield). Technicals are supportive due to a strong uptrend, but the very high RSI suggests the stock may be overextended in the near term, moderating the overall score.
Positive Factors
Free Cash Flow Strength
Very strong free cash flow growth and near-complete conversion of earnings into FCF provide durable internal funding for R&D, capital expenditure, dividends or buybacks. This reduces reliance on external financing and supports strategic investment and shareholder returns over the medium term.
Negative Factors
Modest Revenue Growth
Revenue growth is modest, which may limit upside from scale and reduce leverage on fixed costs. In a competitive diagnostics market, slower top-line expansion can constrain long-term margin expansion and returns, making sustained organic growth a key execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Very strong free cash flow growth and near-complete conversion of earnings into FCF provide durable internal funding for R&D, capital expenditure, dividends or buybacks. This reduces reliance on external financing and supports strategic investment and shareholder returns over the medium term.
Read all positive factors
Kainos Laboratories, Inc. (4556) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.27B
Dividend Yield2.53%
Average Volume (3M)3.67K
Price to Earnings (P/E)9.5
Beta (1Y)0.56
Revenue Growth3.14%
EPS Growth-2.85%
CountryJP
Employees133
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)105.98
Shares Outstanding4,558,860
10 Day Avg. Volume3,280
30 Day Avg. Volume3,666
Financial Highlights & Ratios
PEG Ratio-62.73
Price to Book (P/B)0.78
Price to Sales (P/S)1.00
P/FCF Ratio8.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kainos Laboratories, Inc. Business Overview & Revenue Model
Company Description
KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, mar...
How the Company Makes Money
null...
Kainos Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
90
Very Positive
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.31B | 5.06B | 4.92B | 4.61B | 4.26B |
| Gross Profit | 2.61B | 2.48B | 2.45B | 2.35B | 2.25B |
| EBITDA | 919.48M | 977.00M | 956.45M | 897.86M | 775.07M |
| Net Income | 641.02M | 637.97M | 568.17M | 512.33M | 417.40M |
Balance Sheet | |||||
| Total Assets | 8.83B | 8.61B | 8.12B | 7.57B | 6.96B |
| Cash, Cash Equivalents and Short-Term Investments | 3.40B | 3.17B | 3.02B | 2.68B | 2.24B |
| Total Debt | 629.49M | 862.97M | 941.10M | 947.61M | 1.00B |
| Total Liabilities | 2.06B | 2.34B | 2.45B | 2.37B | 2.30B |
| Stockholders Equity | 6.78B | 6.27B | 5.67B | 5.20B | 4.66B |
Cash Flow | |||||
| Free Cash Flow | 633.30M | 356.87M | 536.81M | 463.19M | 518.06M |
| Operating Cash Flow | 704.78M | 430.58M | 544.51M | 604.36M | 591.25M |
| Investing Cash Flow | -71.30M | -72.83M | -10.33M | -141.19M | -117.16M |
| Financing Cash Flow | -411.04M | -203.73M | -191.14M | -31.25M | -194.61M |
Kainos Laboratories, Inc. Technical Analysis
Positive
1271.00
Price Trends
2077.48
Positive
1680.29
Positive
1471.04
Positive
Market Momentum
40.43
Positive
77.32
Negative
78.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1271 is below the 20-day moving average (MA) of 2267.15, below the 50-day MA of 2077.48, and below the 200-day MA of 1471.04, indicating a neutral trend. The MACD of 40.43 indicates Positive momentum. The RSI at 77.32 is Negative, neither overbought nor oversold. The STOCH value of 78.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.
Kainos Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | ¥9.27B | 9.53 | ― | 2.53% | 3.14% | -2.85% | |
73 Outperform | ¥3.21T | 25.64 | 8.98% | 1.22% | 7.68% | 10.08% | |
71 Outperform | ¥877.10B | 16.38 | 9.38% | 1.88% | 1.51% | -12.59% | |
68 Neutral | ¥954.90B | 24.33 | 11.64% | 0.82% | 13.53% | -7.39% | |
62 Neutral | ¥266.50B | 5.59 | 4.38% | 2.03% | 6.04% | 733.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4556
Kainos Laboratories, Inc.
2,264.00
1,109.00
96.02%
JP:4543
Terumo
2,171.00
-471.36
-17.84%
JP:7747
Asahi Intecc Co
3,599.00
1,439.22
66.64%
JP:8086
Nipro
1,634.00
364.93
28.76%
JP:6869
Sysmex
1,406.50
-1,195.50
-45.95%
JP:368A
Kitazato Corporation
1,340.00
-418.70
-23.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.